Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.
about
Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson diseaseTime course and progression of wild type α-synuclein accumulation in a transgenic mouse model.Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo.Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases.Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.The role of Galectin-3 in α-synuclein-induced microglial activation.Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathyAccumulation of α-synuclein in dementia with Lewy bodies is associated with decline in the α-synuclein-degrading enzymes kallikrein-6 and calpain-1.A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease.Combination therapies: The next logical Step for the treatment of synucleinopathies?Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathyIdentification of brain-enriched proteins in the cerebrospinal fluid proteome by LC-MS/MS profiling and mining of the Human Protein Atlas.Serotonergic dysfunction in the A53T alpha-synuclein mouse model of Parkinson's disease.Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophyKLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species.Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like PropagationUnleashing the therapeutic potential of human kallikrein-related serine proteases.Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.Therapeutic approaches in Parkinson's disease and related disorders.Endothelin-converting enzymes degrade α-synuclein and are reduced in dementia with Lewy bodies.α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease.Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.Small molecule NPT-440-1 inhibits ionic flux through Aβ1-42 pores: Implications for Alzheimer's disease therapeutics.A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.Kallikrein-related peptidase 6 orchestrates astrocyte form and function through proteinase activated receptor-dependent mechanisms
P2860
Q27005843-255DD509-CA46-42F5-A7BD-BBAFD7F842CBQ30532478-53108402-392E-43E8-93A1-FA4F444B39BDQ30578913-92B1BBCF-02D2-4C15-98C5-A986BA834E38Q30650119-B524C977-DE4E-45F7-9C1C-D2B4E2DDF77DQ33731321-276A12F5-F7BA-4941-845E-E267751A8909Q34087004-64A706FD-A6C5-4C1C-9352-0239B512A1CDQ34537231-0F8B356D-2F1E-4C73-ACD9-692EC1ED46DFQ34544824-BEE7FE70-66E9-49A1-B2C1-3105E660DF2EQ34739881-3E1FA523-7501-468E-B9CD-976B018310AEQ36086721-0066268D-112E-439C-9147-974072E95580Q36484413-80C916E4-F2E7-423C-B12B-8B519E9ABEC9Q36489317-350E1947-C378-4433-A16D-7C9C74651787Q36563062-B16A0C3B-D295-4268-A10E-579933751B09Q36672116-24D5B744-2FEB-417C-BBB7-AC4B25BB5572Q36904004-57DD7E9B-AF3E-4E32-9698-DBDA254DCE7CQ37092527-6680C956-3DC8-4150-90AD-B1DEC178E860Q37565960-C73DF167-A1A5-4AF4-BDEA-81A3378BA94EQ37716380-6137A35D-DE73-418E-8A9F-F8688AC4F732Q38303579-3AAD3C62-CB91-4C0D-BB70-CC33C797D951Q38362486-6CFDA451-57B2-46BF-9211-A6CB4C561A05Q38652662-A2840283-608F-41A7-A3F3-C8C07E48FC1CQ38691406-EF8E2785-90A5-4106-8B9F-06E9E8878324Q38717493-01304771-BFA3-4419-AF70-F2E9D618EE3CQ41117719-9F82721D-8023-45ED-AD91-077CBDB784C6Q42095746-55A8C019-39B9-40D3-9C0E-A53D7675E436Q42756593-2355CD92-6F57-4651-95BA-C77AE028A3C9Q48493933-87C84978-2B68-4EA9-91C7-54A0E1D5F9F0Q58699560-5C6E5A70-10DE-4E93-A35A-F7B3CE2854AB
P2860
Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Lentivirus mediated delivery o ...... n an α-synuclein model of LBD.
@ast
Lentivirus mediated delivery o ...... n an α-synuclein model of LBD.
@en
type
label
Lentivirus mediated delivery o ...... n an α-synuclein model of LBD.
@ast
Lentivirus mediated delivery o ...... n an α-synuclein model of LBD.
@en
prefLabel
Lentivirus mediated delivery o ...... n an α-synuclein model of LBD.
@ast
Lentivirus mediated delivery o ...... n an α-synuclein model of LBD.
@en
P2093
P2860
P356
P1433
P1476
Lentivirus mediated delivery o ...... n an α-synuclein model of LBD.
@en
P2093
Anthony Adame
Brian Spencer
Christina Patrick
Kori Kosberg
Sarah Michael
P2860
P356
10.1038/MT.2012.66
P577
2012-04-17T00:00:00Z